Bydureon FDA Approved Drugs
BYDUREON [Exenatide Synthetic]
RX
- 2mg/vial (subcutaneous for suspension, extended release)
Astrazeneca AbJan 27, 2012
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
- Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
- Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
- Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
- Reductions in body weight are observed with exenatide.
- Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
- Treatment of type 2 diabetes.
BYDUREON PEN [Exenatide Synthetic]
RX
- 2mg (subcutaneous for suspension, extended release)
Astrazeneca AbFeb 28, 2014
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
- Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
- Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
- Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
- Reductions in body weight are observed with exenatide.
- Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
- Treatment of type 2 diabetes.
BYETTA [Exenatide Synthetic]
RX
- 300mcg/1.2ml (250mcg/ml) (subcutaneous injectable)
600mcg/2.4ml (250mcg/ml) (subcutaneous injectable)
Astrazeneca AbApr 28, 2005
- Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
- Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
- Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
- Stimulating insulin release by administering exenatide.
- Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
- Use of exenatide may result in reduction in appetite..
- Use of exenatide may result in reduction in body weight.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.